• Globe Newswire

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Globenewswire -

• Globe Newswire

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Globenewswire -

• Globe Newswire

Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer

Globenewswire -

• Globe Newswire

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition

• Globe Newswire

Boehringer Ingelheim expands cancer research at its Vienna site

• Globe Newswire

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

• Globe Newswire

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio